Inotiv, Inc.
Severe listing-compliance risk
The share price is below $1 and the stored reverse-split/listing-risk level is CRITICAL. No verified reverse-split authorization or announced reverse split is currently recorded. This is a risk signal, not confirmation that Nasdaq has issued a deficiency notice.
NOTV · Price history
Price chart data is not currently available.
Company & revenue
About Inotiv, Inc.
Primary reporting period: 2025-09-30 · Research updated Oct 13, 2026. A research update is not a new financial filing.
Who they are
Inotiv, Inc. provides nonclinical and analytical drug discovery and development services to the pharmaceutical and medical device industries in the United States, the Netherlands, and internationally. The company operates through two segments, Discovery and Safety Assessment (DSA) and Research Models and Services (RMS). The DMS segment manufactures scientific instruments for life sciences research and the related software for use by pharmaceutical companies, universities, government research centers, and medical research institutions under the company’s BASi product line.
How they make money
Inotiv operates as a contract research organization (CRO) that generates revenue by providing nonclinical and analytical drug discovery and development services to pharmaceutical, biotechnology, and medical device companies. The company also derives income from the sale of research models and related products, charging clients for specialized laboratory services, scientific expertise, and the supply of biological research materials used in drug development pipelines.
Products & services
Nonclinical and analytical drug discovery and development services, research models, and related laboratory products.
Brands & revenue mix
No separate brand or brand-level revenue disclosure was confirmed in the reviewed sources. This does not mean the company has no brands.
Product / operating segments
Geographic revenue
No reconciled geographic revenue breakdown was confirmed for the current research period.
Customer types
Customer concentration
No quantified customer-concentration disclosure is available in the current saved research.
Suppliers, materials & equipment
- Laboratory equipment and consumable manufacturers — Various third-party vendors providing specialized laboratory equipment, reagents, and animal feed; specific supplier names are not disclosed.Source
Strengths
Wall Street Score
Overall investment score · Quality, value, risk and opportunity
17
Poor
View category scores →
Company Quality
How good is the actual business—regardless of today’s stock price?
24
Poor
Financial Strength
17
Business Quality / Moat
60
Management
0
Growth Quality
23
Risk / Durability
6
Uses financial strength, moat, management, growth quality and durability. It excludes share price, P/E, market cap, intrinsic value and margin of safety.
Opportunity
Opportunity Score · How does the current price compare with estimated value?
27
Avoid
Based on current valuation, company quality, recent trends, and available market signals.
View score details →
Model Outlook
12-month model · What does the model think happens next?
38/100
Building Historical Record
Model Score 38/100 — estimates relative performance potential, distinct from the overall Wall Street Score and the separate Company Quality score.
Probability unavailable — the model has not produced a calibrated probability yet.
Click for full breakdown →
Reverse-split / listing-compliance risk: CRITICAL
This is a risk signal, not a prediction. It is separate from Wall Street Score and does not change the company score. It looks for listing-pressure signals such as prolonged Nasdaq trading below $1, very low share price, micro-cap size, negative free cash flow, and verified recent reverse splits.
Risk indicator: 75/100
WSS View
The quick read
The overall Wall Street Score is low across its combined quality, valuation and risk inputs. This can reflect an expensive share price, business weaknesses, or both; check Company Quality and the category breakdown before drawing a conclusion.
At today’s price, the WSS valuation framework currently reads as less attractive based on the available valuation and market data.
The model outlook is currently cautious.
No strong positive signal is being highlighted from the currently available summary data.
- •Material dilution — approximately 25.3% share-count growth
- •Elevated debt risk
- •Valuation is a weaker part of the current profile
- •Revenue fundamentals are weak
- •Debt / balance-sheet profile needs attention
Company-specific research
Questions worth answering for NOTV
These questions are generated from this company's current financial and score data so the page adds context instead of treating the headline score as a stand-alone conclusion.
- •What is driving NOTV's revenue decline, and does the latest company filing suggest the weakness is temporary or structural?
- •How long can NOTV fund negative free cash flow using its current cash position before it may need more debt or new shares?
- •Is NOTV's debt load manageable relative to cash generation, interest costs and upcoming maturities?
- •What specifically needs to improve for NOTV to reach sustainable profitability?
- •What future growth or profitability would be needed to justify NOTV's current valuation?
Essential Investment Snapshot
Wall Street Score
17
Opportunity Score
27
Market Cap
$2.8M
P/E Ratio
-0.0
EPS
$-2.53
52-Week High
$2.44
52-Week Low
$0.02
Beta
4.08
Analyst Target
$6.00
Shares Outstanding
32.5M
Total Revenue
$507.4M
Total Debt
$487.8M
Dividend
No current dividend
Liquidation Value / Share
$2.38
Momentum & Volatility Signals
Two different market-behavior signals. Momentum measures direction and trend strength. Volatility measures how large and unstable the price moves are, regardless of direction.
Notices for NOTV
Detected from reported data — verify before acting.Material dilution — approximately 25.3% share-count growth
Diluted shares outstanding grew ~25.3% year-over-year. Substantial dilution reduces per-share value and can signal financing stress. Wall Street Score is capped.
Elevated debt risk
Interest coverage is below 2x • Free cash flow is negative • Cash covers less than 20% of total debt
Community Sentiment
0 active · 0 total callsNo personal call yet on NOTV.
Potential upside factors
- +Growth opportunities may come from revenue expansion, margin improvement, new products, market-share gains, and stronger cash flow.
- +Integrated nonclinical and analytical service offerings.
- +Specialized expertise in drug discovery and development.
Potential downside factors
- −Debt risk (elevated): Interest coverage is below 2x.
- −Free cash flow is negative.
- −Cash covers less than 20% of total debt.
- −Dependence on the pharmaceutical and biotechnology research and development spending environment.
These research factors come from saved company research and financial data, not community votes. They are starting points to verify against filings, not buy or sell recommendations.
Create a free account to make a call.
Scores
Click any score for full breakdownWas this stock page easy to understand?
One click helps us improve the research experience. This is not tied to an investment decision.
Score Changes
3 historical score records availablePrevious Score
17
Oct 1, 2026
Change
Unchanged
Current Score
17
Oct 8, 2026
Category Changes
NOTV score was unchanged.
Projected Score
Projected Score
14
Projected Change
-2.4 points
Preliminary comparable-period financial changes suggest decline of approximately 2.4 points. This is a projected estimate, not the official WallStreetScore.
Price vs. Value
Valuation unavailableCurrent Price
$0.08
Model Intrinsic Value
—
Difference
—
Margin of Safety
—
Intrinsic value is not currently available for this stock, so valuation can't be calculated.
Financial Charts
Revenue
Additional Metrics
Operating Cash Flow
Total Debt
Total Assets
Net Margin %
Free includes 3 annual periods plus available TTM; Premium includes up to 10 annual periods. History depends on available company filings. Swipe the table horizontally to see older periods. A dash means unavailable, not zero.
| Line Item | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $507.4M | $513.0M | $490.7M | $572.4M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Cost of Revenue | $432.8M | $448.0M | $379.6M | $407.0M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Gross Profit | $74.6M | $65.1M | $111.2M | $165.4M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Research & Development | $0.00 | $0.00 | $0.00 | $0.00 | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| SG&A Expenses | $92.9M | $92.2M | $97.9M | $127.3M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Operating Expenses | $119.6M | $96.0M | $197.6M | $246.9M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| EBITDA | $10.2M | $24.8M | -$26.8M | -$26.5M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Operating Income | -$45.0M | -$30.9M | -$86.4M | -$81.5M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Interest Expense | $56.8M | $56.6M | $46.9M | $43.0M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Income Before Tax | -$105.7M | -$87.8M | -$130.8M | -$124.2M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Income Tax Expense | -$18.8M | -$19.1M | -$21.9M | -$19.3M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Net Income | -$87.0M | -$68.6M | -$108.4M | -$105.1M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Basic EPS | $-2.53 | $-2.11 | $-4.19 | $-4.10 | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Basic Shares | 34.65M | 32.45M | 25.90M | 25.64M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Diluted Shares | 34.65M | 32.45M | 25.90M | 25.64M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
Earnings Summary
Revenue
$117.7M
Estimate unavailable.
Revenue Beat/Miss
Not available (no estimate stored)
EPS
-$0.94
Estimate unavailable.
EPS Beat/Miss
Not available (no estimate stored)
Debt Change
+8.0%
Cash Change
-21.3%
Margin Change
-15.6 pp
Debt and cash show percentage changes versus the comparison period; margin shows the change in percentage points (pp). These are company-wide changes, not per-share amounts.
Financial Changes Since Prior Period
What Weakened
- Margins contracted
- Cash position declined
- Debt increased
Potential Score Impact
Positive indicators included EPS growth. Pressure indicators included revenue growth, cash levels, debt levels, net income margin. These factors may support or pressure the Revenue, Management, Financial, and Debt categories; this summary does not claim that the stored scores changed.
Stored Earnings Analysis
Revenue declined 5.4%. EPS increased 113.6%. Cash declined 21.3%. Total debt increased 8.0%. Net income margin declined by 15.6 percentage points.
Earnings-Call Transcript
Earnings-call transcript analysis is not currently available.
These results may influence future scores when the next evaluation is completed.
Insider Activity
Guru / Smart Money
Guru Score
Smart Money
Number of Gurus
Total Guru Value
Avg Portfolio Weight
Largest Holder
Largest Holder %
New Positions
Increased Positions
Reduced Positions
Exited Positions
Net Guru Sentiment
Short Interest
Dividend History
Dividend data is not available yet. Missing data does not mean this company pays no dividend.
Conservative Projected Values
3 Years
$———.——
5 Years
$———.——
10 Years
$———.——
Conservative Projection Rate
——%
Conservative Projected Values — price projections derived from actual 10-year adjusted historical returns, conservatively adjusted and capped at 8% annually. These are distinct from the Outperformance Model Score and WallStreetScore.
Conservative Projected Values
Premium unlocks the 3-year, 5-year, and 10-year conservative projected values with full calculation breakdowns based on actual historical returns.
Start 7-Day Free TrialHistorical Outperformance Record
Premium includes stored forecasts and any available evaluated results. Completed results, win rates and calibrated probabilities are shown only when supported records exist; access does not create historical outcomes.
Start 7-Day Free TrialHistorical Trends
3 historical recordsHistorical Score Chart
3 of 3 records shownWall Street Score
Debt Score
Revenue Score
Asset Score
Capital Score
Management Score
Moat Score
Valuation Score
Buffett Score
Intrinsic Value
Value Reference
Margin of Safety %
Related Companies
Medical - Diagnostics & ResearchNews
No news available for NOTV.
Rumor Mill · NOTV
Corporate developments & opportunities
No reviewed developments match this filter.
Evidence credibility is not a forecast of stock performance. Rumor Mill is separate from the WSS score.
Related Stock Research
Continue researching this company with related Wall Street Score rankings and investing guides.
Score Alerts
Premium unlocks alerts when a score rises, falls, or reaches your target price.
Start 7-Day Free TrialPortfolio Score
Premium unlocks portfolio scoring, strongest and weakest holdings, and overall margin of safety.
Start 7-Day Free Trial